Compare HNVR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | VYGR |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 193.5M |
| IPO Year | 2022 | 2015 |
| Metric | HNVR | VYGR |
|---|---|---|
| Price | $24.04 | $2.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $27.33 | $14.89 |
| AVG Volume (30 Days) | 24.2K | ★ 739.1K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $129.75 |
| P/E Ratio | $30.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.89 |
| 52 Week High | $27.94 | $5.19 |
| Indicator | HNVR | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 25.01 |
| Support Level | $22.27 | N/A |
| Resistance Level | $24.38 | $4.29 |
| Average True Range (ATR) | 0.95 | 0.13 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 9.45 | 12.72 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.